Abstract:Background Circulating levels of IL-8 is related to the bone loss associated with breast cancer metastasis. Recently, we have shown that anti-citrullinated protein antibodies (ACPA) can induce osteoclastogenesis. Objectives We aimed to investigate the role of IL-8 and its receptors in mediating osteoclastogenesis in presence or absence of ACPAs Methods IL-8 levels was measured by ELISA in serum of risk RA patients and synovial fluid samples of RA patients. CD14 positive monocytes were used to generate osteoclasts with M-CSF and RANKL. Inhibition of IL-8 and its receptor were tested with IL-8 neutralizing antibody or small molecule CXCR1/2 anta-agonist (Reparixin and SCH-527123) on osteoclasts (OC) in the presence or absence of ACPA. The number of the OC9s were counted in light microscope after TRAP staining. Cell counting kit 8 (CCK8) assay was performed to detect cytotoxicity. CXCR1 and CXCR2 expression was analyzed using flow cytometry and immunohistochemistry during different days of osteoclasts maturation. Results Increased IL-8 levels were observed in the serum of ACPA positive at risk RA healthy individuals and in synovial fluid of established ACPA positive RA patients. Exogenous IL-8 dose dependently increased OC numbers in presence of RANKL. IL-8 neutralizing antibody inhibited the OC numbers even in the presence of ACPA. Reparixin and SCH-527123 significantly inhibited RANKL mediated osteoclastogenesis at 100 μM concentration. No cytotoxicity of the drugs were detected with CCK8 assay. Immunohistochemistry staining confirmed the CXCR1/2 expression on OC precursors. We found high expression of IL-8 using immunohistochemistry on the inflammed RA synovium.We observed CXCR1 and CXCR2 expression with flow cytometry in the OC precursors at day 0 and in presence of RANKL the expression was completely lost at day 1 and it reappeared at day 4. Conclusions Our data provides insights in to the importance of IL-8 autocrine loop in RANKL and ACPA mediated OC development. IL-8 receptor blockade might be a novel way of targeting bone loss in RA. Disclosure of Interest None declared

Serum amyloid A inhibits osteoclast differentiation to maintain macrophage function

Serum Amyloid A Induces M2 Macrophage-Specific Genes Expression and Promotes Efferocytosis of Apoptotic Neutrophils (P5072)

Ex Vivo and In Vitro Effect of Serum Amyloid A in the Induction of Macrophage M2 Markers and Efferocytosis of Apoptotic Neutrophils

Serum Amyloid A Was Correlated with Osteonecrosis of the Femoral Head by Affecting Bone Metabolism

Serum Amyloid A Exhibits Ph Dependent Antibacterial Action and Contributes to Host Defense Against Staphylococcus Aureus Cutaneous Infection.

Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5

Jmjd3-mediated Epigenetic Regulation of Inflammatory Cytokine Gene Expression in Serum Amyloid A-stimulated Macrophages.

Emerging Functions Of Serum Amyloid A In Inflammation

Class A Scavenger Receptor Exacerbates Osteoclastogenesis by an Interleukin-6-Mediated Mechanism through ERK and JNK Signaling Pathways

Serum Amyloid a Attenuates Tau Phosphorylation in a Systemic Inflammation Model

Serum Amyloid A Correlates With the Osteonecrosis of Femoral Head by Affecting Bone Metabolism

Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway.

Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1

Serum amyloid protein A in inflammatory bowel disease: from bench to bedside

Serum Amyloid A Inhibits Astrocyte Migration Via Activating P38 MAPK

Role Of Il-8 And Its Receptor In Anti-Citrullinated Protein Antibody Mediated Osteoclastogenesis In Ra

Microbial chaperonin 60 inhibits osteoclast differentiation by interfering with RANK/RANKL binding and overexpression of lipocalin2

Serum Amyloid a Differentially Activates Microglia and Astrocytes Via the PI3K Pathway.

Serum Amyloid A Activates Peroxisome Proliferator-Activated Receptor Γ Through Extracellularly Regulated Kinase 1/2 and COX-2 Expression in Hepatocytes.

A2M Inhibits Inflammatory Mediators of Chondrocytes by Blocking IL‐1β/NF‐κB Pathway